Streetbeat News

RAPP

Rapport Therapeutics Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

10.43

Mkt cap

384M

Volume

186K

High

11.34

P/E Ratio

-2.78

52-wk high

29.74

Low

10.29

Div yield

N/A

52-wk low

6.43

Rapport Therapeutics ended the quarter with $336.1 million in cash, cash equivalents, and short-term investments, excluding restricted cash. This funding is expected to support operations through the end of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:58 am

Rapport Therapeutics reported a Q2 2024 GAAP EPS of $(1.70), missing the estimate of $(0.68).

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:57 am

TD Cowen has initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating, as announced by analyst Joseph Thome.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 2:12 pm

Jefferies has initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 12:04 pm

Stifel analyst Paul Matteis initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and sets a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:55 am

Shares of Contango Ore, Inc. (NYSE:CTGO) fell sharply by 18.4% after the company announced a $15 million underwritten public offering. Other notable stock movements include Trio Petroleum Corp. (NYSE:TPET) jumping 88.2% after completing its first two exploratory wells, and Airship AI Holdings, Inc. (NASDAQ:AISP) climbing 32.5% following a contract award from the Department of Justice.

Portfolio Pulse from Avi Kapoor

June 11, 2024 | 5:54 pm

Rapport Therapeutics IPO shares opened for trade at $18 per share, after being priced at $17 on 8 million shares.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 3:07 pm

Rapport Therapeutics has set its IPO price at $17 per share for 8 million shares, with an initial trading price indicating $18.05 on 350,819 shares.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 2:58 pm

Rapport Therapeutics has set its IPO price at $17 per share, with 8 million shares being offered. The IPO price indicates a potential value of $18 per share on 276,000 shares.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 2:42 pm

Rapport Therapeutics has set its IPO price at $17 per share for 8 million shares, with an indication of $18 per share on 196,335 shares.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 2:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.